GSK Looks Forward To RSV Vaccine Competition

Things are looking up for the UK company with growing dominance for Arexvy among respiratory syncytial virus shots and international growth for shingles vaccine Shingrix

GSK

GSK has got the year off to a good start thanks to strong growth from vaccines Shingrix and Arexvy, with the latter expected to gain an expanded US license by mid-2024.

That has instilled a growing sense of momentum at the company, with CEO Emma Walmsley commenting that she "welcomed" competition...

More from Business

More from Scrip